Bill Hyun
Venture Partner at Genoa Ventures
San Francisco, California
Overview
Work Experience
Department of Laboratory Medicine
1985 - Current
UCSF scientist over twenty-five (25) years, twenty-three as Director of the Laboratory for Cell Analysis (LCA). Currently Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine. • Built the LCA into one of the largest academic cytometry core facilities worldwide. • Direct contribution to grants totals well over $40M in extramural funding. • Helped design and build five commercial flow cytometers, two cell sorters, and two commercial confocal microscopes. Current work supports several developing technology fields including automated digital pathology and laser-based microdissection systems, next generation clinical cell sorters, spectral flow cytometry, chip-based cytometry and point-of-care devices, wide-field high-resolution deep tissue confocal microscopy, mass spec flow cytometry (CyTOF), and spectral in vivo imaging. Application development includes single cell genomics, new functional reporter probes for cell cycle, cellular biosensors, FRET/FRAP/FLIM reporters for monitoring protein and drug interactions, new encoded carrier technology for immune profiling and liquid arrays, and rapid identification systems for virology and microbiology. Hyun also participates in biomedical software and database design, and testing of new algorithms for cytometric data processing and presentation of results.
Venture Partner
2018
Genoa Ventures invests in early-stage life sciences companies innovating at the intersection of biology, technology, and data science. From next-gen 'omics platforms to CRISPR-Cas genome editing, our portfolio companies are transforming biomedical research, diagnostics, agriculture, chemicals, and other industries beyond traditional biotech therapeutics.
Genoa Ventures is a venture capital firm that invests in early-stage life sciences technology companies.
Board Member and Co-Founder
2018
Fluent Biosciences is developing an instrument-free genomic partitioning technology.
Fluent Biosciences, a life science company, offering a molecular analysis of cells without the use of complex microfluidic instrumentation.
Raised $22,900,000.00 from National Institute of General Medical Science, National Institute of General Medical Science and Small Business Innovation Research.
Board Member
2014
Slingshot Biosciences aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. Our technology platform will make a significant bottom-line impact on the speed and cost of early-stage discovery, research and development programs. http://www.slingshotbio.com/
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Raised $49,227,275.00 from Northpond Ventures, Anterra Capital, ARCH Venture Partners, Northpond Ventures, ARCH Venture Partners and Anterra Capital.
Board Member
2016
Akadeum Life Sciences, a biotechnology start-up redefining the means by which cells and bacteria are sorted from real-world samples. With applications in industrial, pre-clinical, and clinical life sciences, Akadeum technology is rapidly being adopted by labs looking for alternatives to magnetic bead and flow cytometry based cell sorting.
Board Member
2018
Scribe's core technology, Microenvironment on Demand (MOD), enables the construction of hundreds of thousands of live cell-based assays (cytotoxicity, secretion) in droplets and selectively profile assay-positive droplets using genomics readouts. MOD will enable deeper understanding of cancer, heart and autoimmune diseases by linking live-cell assays to genomics at a single-cell resolution.
Board Member
2005
Newbridge Media LLC is a holding company of media operations and brands dedicated to search-based publishing and independent journalism.
Newbridge Media LLC is a holding company of media operations and brands dedicated to search-based publishing and independent journalism.
Scientific Advisor and Investor
2018
CellFE develops microfluidic devices and processes that can efficiently deliver gene-editing molecules into human cells
Former Board Member, Scientific Advisor and Investor
2014
Mission Bio provides tools for the study of cellular heterogeneity in human health and life science research. Our approach relies on proprietary microfluidic droplet technology to deliver rapid and cost-effective solutions for molecular analysis of single cells. Bill was the first investor.
Mission Bio develops only single-cell multi-omics platform integrating genotype and phenotype for cancer research and biomarker development.
Raised $150,898,729.00 from Novo Holdings, Cota Capital, Soleus Capital, Mayfield Fund, Seabed VC and Agilent Ventures.
Scientific Advisor and Investor
2015
Applaud Medical, Inc. was established to develop and commercialize an innovative new treatment for kidney stones, a condition diagnosed in more than 2 million individuals every year in the U.S. alone. Treating large stones currently requires anesthesia in an operating room . The current least invasive surgical intervention only renders 50% of patients stone-free. Applaud’s innovative kidney stone treatment will - for the first time - allow urologists to effectively treat 5-15 millimeter stones with a simple outpatient procedure.